Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effect of Immune X on Common Cold Incidence in Healthy Adults (CELFI)

21. august 2026 opdateret af: Givaudan France Naturals

The Effect of Immune X on the Incidence of the Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

The goal of this clinical trial is to learn if Immune X can help prevent common cold events in healthy adults who have a history of upper respiratory tract infections. The main questions it aims to answer are:

  • Does Immune X reduce the proportion of participants who experience at least one clinically confirmed common cold event during the study period?
  • Does Immune X affect the number, duration, and severity of common cold events?

Researchers will compare Immune X to a placebo (a look-alike capsule containing inactive ingredients) to see if Immune X helps prevent common cold events.

Participants will:

  • Take Immune X or placebo daily for 16 weeks during the winter season.
  • Attend study visits at the beginning and end of the study and complete questionnaires and symptom assessments throughout the study.
  • Record cold symptoms, medications, and other study information using a smartphone application.
  • Provide blood and stool samples during the study.

Studieoversigt

Status

Ikke rekrutterer endnu

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

160

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Men and women aged 18 to 65 years.
  • History of at least two upper respiratory tract infections during the previous winter season.
  • Body mass index between 18 and 30 kg/m².
  • Generally healthy, as determined by the investigator.
  • Women of childbearing potential must have a negative pregnancy test and agree to use an effective method of contraception during the study.
  • Covered by French health insurance.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • Current or recent upper respiratory tract infection or COVID-19 infection within 2 weeks before enrollment.
  • Acute gastrointestinal infection, including gastroenteritis, within 2 weeks before enrollment.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before enrollment.
  • Use of systemic antibiotics within 3 months before enrollment.
  • Receipt of any vaccination within 6 weeks before enrollment.
  • Surgery requiring general anesthesia within 1 month before enrollment.
  • History of chronic respiratory disease, including asthma or chronic obstructive pulmonary disease.
  • Food allergy or chronic/recurrent allergic upper airway conditions requiring regular medical treatment, including moderate to severe allergic rhinitis, hay fever, or chronic rhinosinusitis.
  • Acute lower respiratory tract infection within 6 months before enrollment or ongoing long COVID.
  • Immunodeficiency (including HIV infection) or autoimmune disease, except stable hypothyroidism.
  • Severe or uncontrolled chronic disease, including cancer, significant liver, pancreatic, biliary, or renal disease, inflammatory bowel disease, or cardiovascular disease requiring intensive medical management.
  • Untreated or inadequately controlled diabetes.
  • History or current diagnosis of periodontitis.
  • Current chemotherapy, immunosuppressive therapy, or chronic treatment with corticosteroids or opioids.
  • Specific diets or major dietary changes within 3 months before enrollment, including high-protein, vegan, low-calorie, or low-FODMAP diets, or participation in a weight-loss program.
  • Current use of dietary supplements that may affect immune or gut microbiota parameters, or discontinuation of such supplements less than 6 weeks before enrollment.
  • Current smoking or e-cigarette use, or smoking cessation within 6 months before enrollment.
  • Current drug or alcohol abuse, or a history of abuse within the previous 12 months.
  • Regular consumption of more than 2 alcoholic drinks per day and unwillingness to maintain stable drinking habits during the study.
  • Unwillingness to refrain from using over-the-counter cold remedies, nasal washes or sprays, antihistamines, corticosteroids, or NSAIDs during the study.
  • More than 8 hours per week of vigorous physical activity or planned major changes in physical activity during the study.
  • Any condition or circumstance that, in the investigator's judgment, may place the participant at unacceptable risk or interfere with study participation or interpretation of study results.
  • Current participation in another clinical trial or being in an exclusion period from a previous clinical trial.
  • Pregnant or breastfeeding.
  • Persons deprived of liberty, under legal protection, or unable to provide informed consent.
  • Individuals who have reached the regulatory compensation limit for participation in clinical research.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Immune X
80 participants who meet the eligibility criteria will be randomized to the experimental arm and will receive Immune X for 16 weeks.
500 mg Immune X daily as capsules for 16 weeks.
Placebo komparator: Placebo
80 participants who meet the eligibility criteria will be randomized to the placebo arm and will receive placebo for 16 weeks.
Matching placebo capsules daily for 16 weeks.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Participants With at Least One Clinically Confirmed Cold Event
Tidsramme: Week 2 to Week 16
Proportion of participants with at least one clinically confirmed cold event.
Week 2 to Week 16

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Clinically Confirmed Cold Events
Tidsramme: Week 2 to Week 16
Mean number of clinically confirmed cold events per participant.
Week 2 to Week 16
Duration of Clinically Confirmed Cold Events
Tidsramme: Week 2 to Week 16
Duration of clinically confirmed cold events measured in days.
Week 2 to Week 16
Upper Respiratory Symptoms of Clinically Confirmed Cold Events
Tidsramme: Week 2 to Week 16
Wisconsin Upper Respiratory Symptom Survey (WURSS-24): Zero is equivalent to no symptoms and 7 indicates severe.
Week 2 to Week 16
Cold Symptoms of Clinically Confirmed Cold Events
Tidsramme: Week 2 to Week 16
Jackson Cold Scale: 0 is equivalent to absent symptoms and 3 indicates severe symptoms
Week 2 to Week 16
Illness-Specific Quality of Life During Cold Events
Tidsramme: Week 2 to Week 16
Wisconsin Upper Respiratory Symptom Survey (WURSS-24) quality-of-life score: Zero is equivalent to no interference and 7 indicates severe interference.
Week 2 to Week 16
Time to First Clinically Confirmed Cold Event
Tidsramme: Week 2 to Week 16
Number of days from Day 15 after randomization to the first clinically confirmed cold event.
Week 2 to Week 16
Fatigue
Tidsramme: Baseline, Weeks 4, 8, 12, and 16
Chalder Fatigue Questionnaire (CFQ-11) total score: 0 is equivalent to less/better than usual and 33 indicates much more/much worse than usual.
Baseline, Weeks 4, 8, 12, and 16
Use of Rescue Medication During Cold Events
Tidsramme: Week 2 to Week 16
Number of doses and duration of rescue medication use during cold events.
Week 2 to Week 16
Number of Cold Events (Clinically Confirmed and Unconfirmed)
Tidsramme: Week 2 to Week 16
Mean number of clinically confirmed and unconfirmed cold events per participant.
Week 2 to Week 16
Adverse Events
Tidsramme: Baseline through Week 16
Number of participants with adverse events.
Baseline through Week 16

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Carole Perrin, MD, Cen Experimental

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. september 2026

Primær færdiggørelse (Anslået)

30. april 2027

Studieafslutning (Anslået)

30. april 2027

Datoer for studieregistrering

Først indsendt

17. august 2026

Først indsendt, der opfyldte QC-kriterier

21. august 2026

Først opslået (Faktiske)

26. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

26. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • C1775
  • 2026-A00903-48 (Anden identifikator: ID-RCB)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner